Brief: Pharmather Initiates Filing Of Abbreviated New Drug Application For Ketarx To The FDA
27/06/2023 13:21
June 27 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER INITIATES FILING OF ABBREVIATED NEW DRUG
APPLICATION
FOR KETARX™ (RACEMIC KETAMINE) TO THE FDA
Source text for Eikon: ID:nGNX5t6MvP
Further company coverage: PHRM.CD
((reuters.briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application